A Phase II Study of Lower Dose Radiation Therapy in People with Metastatic Tumors Containing a Genetic Change


Full Title

Phase II Study to Examine Precision Radiation in Patients with Pathogenic Mutations in ATM


Radiation delivered to metastatic tumors is known to cause damage to the DNA (genetic information) in the cancer cells, which causes them to die. An ATM mutation reduces cancer cells’ ability to fix damage to their DNA, making it more likely that the radiation will kill ATM-mutated cancer cells. Lower doses of radiation therapy may cause fewer side effects than standard doses. In this study, researchers will observe the side effects of reduced-dose radiation therapy in patients with metastatic tumors that contain an ATM mutation and the rate at which tumors grow back (recur) after this treatment. It is hoped that lowering the radiation dose will be effective while reducing the side effects of treatment.

Who Can Join

To be eligible for this study, patients must meet several criteria, including but not limited to the following:

  • Patients must have metastatic cancer that contains an ATM mutation.
  • Patients should be candidates for palliative radiation therapy.
  • Patients must be able to walk and do routine activities for more than half of their normal waking hours.
  • This study is for patients age 18 and older.

For more information about this study and to inquire about eligibility, please contact Dr. Amy Xu at 646-888-6863.




Phase II (phase 2)

Disease Status

Relapsed or Refractory



ClinicalTrials.gov ID